This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

E4_AMINO

Disorders of glycine metabolism

DOID Endpoint Browser

E4_GLYCINE

No definition available.

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E72.5 Cause of death: ICD-10 — E72.5 2 out of 7 registries used, show all original rules.	21
4. Check minimum number of events None	21
5. Include endpoints None	21
6. Filter based on genotype QC (FinnGen only)	21

Control definitions (FinnGen only)

Control exclude: E4_METABOLIA

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: E72
Name in latin: Perturbationes metabolismi glycini

NAME	E4_GLYCINE
CONTROL_EXCLUDE	E4_METABOLIA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E725
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E725
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Disorders of glycine metabolism based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	263	130	130
Only index persons	194	97	97
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	61.96	65.93	57.54
Only index persons	64.29	65.93	62.66

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	21	12	9
Unadjusted period prevalence (%)	0.00	0.00	0.00
Median age at first event (years)	57.70	49.26	68.96

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3012544) pH of Venous blood

6.87

2.35

8.6

2.2

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

4.80

2.11

5.8

1.4

2.4

2.2

g/l

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

3.12

1.29

1.2

2.1

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.95

1.22

1.2

2.0

—

(36304419) Bacteria [Presence] in Urine

2.25

0.99

5.5

2.3

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

2.19

0.97

3.0

3.5

1699.7

2105.3

ng/l

—

(3026008) Bacteria identified in Urine by Culture

2.06

0.89

2.7

2.9

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

2.14

0.87

4.2

3.4

—

(40768797) Stomach Pathology biopsy report

2.53

0.83

1.0

1.3

—

(3037467) Urinalysis macro (dipstick) panel - Urine

113

2.14

0.78

5.7

3.8

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.11

0.74

1.2

2.3

—

(3044640) Blood type and Crossmatch panel - Blood

1.91

0.72

3.0

3.2

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.79

0.66

5.2

2.5

—

(3015736) pH of Urine

1.79

0.66

4.7

3.1

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

0.00

0.64

0.0

1.7

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

0.60

0.45

4.6

2.9

—

(3017181) Myelocytes/100 leukocytes in Blood

0.00

0.43

0.0

5.7

—

0.8

—

(3021440) Promyelocytes/100 leukocytes in Blood

0.00

0.43

0.0

5.7

—

0.2

—

(3048689) Calprotectin [Mass/mass] in Stool

0.00

0.43

0.0

1.1

—

91.5

—

(4010399)

0.00

0.42

0.0

1.4

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.44

0.35

2.3

2.9

—

(42870588) Differential panel, method unspecified - Blood

1.44

0.35

3.4

8.4

—

(3021589) Normoblasts [#/volume] in Blood

0.61

0.33

6.0

11.8

0.0

e9/l

—

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

0.00

0.22

0.0

1.9

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.22

0.0

1.3

—

(3013512) EKG study

1.31

0.21

3.0

2.8

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.21

0.0

1.4

—

(3025159) Blasts/100 leukocytes in Blood

0.00

0.21

0.0

5.9

—

0.2

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

1.37

0.21

7.0

2.2

242.4

96.6

ug/l

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.34

0.20

3.8

3.5

—

(3013115) Eosinophils [#/volume] in Blood

0.71

0.19

4.9

7.0

0.2

e9/l

—

(3019198) Lymphocytes [#/volume] in Blood

0.75

0.19

4.9

6.8

1.5

1.8

e9/l

—

(3001604) Monocytes [#/volume] in Blood

0.78

0.19

4.9

6.8

0.5

0.6

e9/l

—

(3006315) Basophils [#/volume] in Blood

0.78

0.19

4.9

6.8

0.0

e9/l

—

(3044889) 12 lead EKG panel

113

1.14

0.09

3.9

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

0.0

1.4

—

(1002224) Polysomnography panel

0.00

0.0

1.2

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

0.00

0.0

1.6

—

(3002030) Lymphocytes/100 leukocytes in Blood

0.90

0.00

4.9

7.7

27.0

28.2

—

(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.0

1.4

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

2.0

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.4

—

(40768795) Lymph node Pathology biopsy report

0.00

0.0

1.2

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

0.00

0.0

1.4

—

(3004248) Sex hormone binding globulin [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

50.2

—

(3029634) Reagin Ab [Titer] in Serum by VDRL

0.00

0.0

1.4

—

(4034850)

0.00

0.0

10.4

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

0.0

1.4

—

(3003327) Ova and parasites identified in Stool by Light microscopy

0.00

0.0

1.8

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.0

1.2

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.1

—

(3019539) Treponema pallidum Ab [Titer] in Serum by Hemagglutination

0.00

0.0

1.3

—

(1761482) Bacteria [#/volume] in Urine by Culture

0.00

0.0

3.5

—

(3000330) Specific gravity of Urine by Test strip

0.00

0.0

2.7

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

162

0.95

0.00

4.9

4.6

6.9

6.0

mmol/l

0.88

142

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.0

1.6

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.00

0.0

2.7

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.0

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

0.98

0.00

8.4

5.2

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.0

—

(3004588) Protein electrophoresis panel - Serum or Plasma

0.00

0.0

1.2

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.00

0.0

1.5

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

9.8

—

165.7

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.3

—

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.0

—

(3002385) Erythrocyte distribution width [Ratio]

140

1.00

0.00

34.3

17.9

14.3

13.8

0.44

133

Mortality – FinRegistry

↥

Association

Association between endpoint E4_GLYCINE and mortality.

Females

Parameter	HR [95% CI]	p-value
E4_GLYCINE	2.408 [1.48, 3.92]	< 0.001
Birth year	0.992 [0.98, 1.0]	0.069

During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 112 females with E4_GLYCINE died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_GLYCINE.

N-year risk	Females	Males
1	0.193%	No data
5	1.165%	No data
10	2.922%	No data
15	5.614%	No data
20	10.372%	No data

Relationships between endpoints

↥

Index endpoint: E4_GLYCINE – Disorders of glycine metabolism

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Disorders of glycine metabolism

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints